Prognostic importance of Mean Platelet Volume/ Platelet Ratio Before Treatment in Patients with Metastatic Pancreatic Cancer

N.A.

Makale detayları

Prognostic importance of Mean Platelet Volume/ Platelet Ratio Before Treatment in Patients with Metastatic Pancreatic Cancer

Yazarlar:

N.A.

Yayıncı:

Dicle University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Dicle Tıp Dergisi Vol.50 Issue 1, pp.51-59

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001285397

pISSN:

1300-2945

Anahtar kelimeler:

Özet:

 Objectives: Pancreatic cancer PC is one of the cancers with the worst prognosis in the world. Despite protooncogenes such as BRCA and PALB2 , effective, inexpensive, and simple methods for predicting the prognosis of patients with metastatic PC are still lacking. We aim to investigate whether mean platelet volume platelet MPVPLT and platelet indices such as MPV and plateletcrit PCT have a prognostic significance in patients with metastatic PC. Methods: Patients diagnosed with metastatic PC in 3 centers in Turkey between 2016 and 2022 were analyzed retrospectively. We recorded patients demographic data such as age, gender, performance status and platelet, MPV and PCT. Overall survival OS and progression-free survival PFS were also recorded. There were 80 patients in our study. Results: Median PFS was found 6.2 months for MPVPLT ratio 0.045 group and 6.3 months for MPVPLT ratio 0.045 group retrospectively. The median PFS of the MPVPLT ratio 0.045 groupwas shorter than MPVPLT ratio 0.045 group, but there wasnt statistically meaningful difference between the groups p:0,957. Median OS for the MPVPLT ratio 0.045 groupwas 10.1 months and the MPVPLT ratio for the 0.045 group was 9 months, but there wasnt statistically significant difference between the groups p:0.506.There was nosurvival difference between the groups when comparing both MPV and PCT status. Conclusion: MPVPLT ratio is a cheap, simple and useful marker and can be used in our daily practice to predict the prognosis of patients with advanced PC, if confirmed by prospective studies and larger patient numbers.

 Objectives: Pancreatic cancer PC is one of the cancers with the worst prognosis in the world. Despite protooncogenes such as BRCA and PALB2 , effective, inexpensive, and simple methods for predicting the prognosis of patients with metastatic PC are still lacking. We aim to investigate whether mean platelet volume platelet MPVPLT and platelet indices such as MPV and plateletcrit PCT have a prognostic significance in patients with metastatic PC. Methods: Patients diagnosed with metastatic PC in 3 centers in Turkey between 2016 and 2022 were analyzed retrospectively. We recorded patients demographic data such as age, gender, performance status and platelet, MPV and PCT. Overall survival OS and progression-free survival PFS were also recorded. There were 80 patients in our study. Results: Median PFS was found 6.2 months for MPVPLT ratio 0.045 group and 6.3 months for MPVPLT ratio 0.045 group retrospectively. The median PFS of the MPVPLT ratio 0.045 groupwas shorter than MPVPLT ratio 0.045 group, but there wasnt statistically meaningful difference between the groups p:0,957. Median OS for the MPVPLT ratio 0.045 groupwas 10.1 months and the MPVPLT ratio for the 0.045 group was 9 months, but there wasnt statistically significant difference between the groups p:0.506.There was nosurvival difference between the groups when comparing both MPV and PCT status. Conclusion: MPVPLT ratio is a cheap, simple and useful marker and can be used in our daily practice to predict the prognosis of patients with advanced PC, if confirmed by prospective studies and larger patient numbers.

 Objectives: Pancreatic cancer PC is one of the cancers with the worst prognosis in the world. Despite protooncogenes such as BRCA and PALB2 , effective, inexpensive, and simple methods for predicting the prognosis of patients with metastatic PC are still lacking. We aim to investigate whether mean platelet volume platelet MPVPLT and platelet indices such as MPV and plateletcrit PCT have a prognostic significance in patients with metastatic PC. Methods: Patients diagnosed with metastatic PC in 3 centers in Turkey between 2016 and 2022 were analyzed retrospectively. We recorded patients demographic data such as age, gender, performance status and platelet, MPV and PCT. Overall survival OS and progression-free survival PFS were also recorded. There were 80 patients in our study. Results: Median PFS was found 6.2 months for MPVPLT ratio 0.045 group and 6.3 months for MPVPLT ratio 0.045 group retrospectively. The median PFS of the MPVPLT ratio 0.045 groupwas shorter than MPVPLT ratio 0.045 group, but there wasnt statistically meaningful difference between the groups p:0,957. Median OS for the MPVPLT ratio 0.045 groupwas 10.1 months and the MPVPLT ratio for the 0.045 group was 9 months, but there wasnt statistically significant difference between the groups p:0.506.There was nosurvival difference between the groups when comparing both MPV and PCT status. Conclusion: MPVPLT ratio is a cheap, simple and useful marker and can be used in our daily practice to predict the prognosis of patients with advanced PC, if confirmed by prospective studies and larger patient numbers.

 Objectives: Pancreatic cancer PC is one of the cancers with the worst prognosis in the world. Despite protooncogenes such as BRCA and PALB2 , effective, inexpensive, and simple methods for predicting the prognosis of patients with metastatic PC are still lacking. We aim to investigate whether mean platelet volume platelet MPVPLT and platelet indices such as MPV and plateletcrit PCT have a prognostic significance in patients with metastatic PC. Methods: Patients diagnosed with metastatic PC in 3 centers in Turkey between 2016 and 2022 were analyzed retrospectively. We recorded patients demographic data such as age, gender, performance status and platelet, MPV and PCT. Overall survival OS and progression-free survival PFS were also recorded. There were 80 patients in our study. Results: Median PFS was found 6.2 months for MPVPLT ratio 0.045 group and 6.3 months for MPVPLT ratio 0.045 group retrospectively. The median PFS of the MPVPLT ratio 0.045 groupwas shorter than MPVPLT ratio 0.045 group, but there wasnt statistically meaningful difference between the groups p:0,957. Median OS for the MPVPLT ratio 0.045 groupwas 10.1 months and the MPVPLT ratio for the 0.045 group was 9 months, but there wasnt statistically significant difference between the groups p:0.506.There was nosurvival difference between the groups when comparing both MPV and PCT status. Conclusion: MPVPLT ratio is a cheap, simple and useful marker and can be used in our daily practice to predict the prognosis of patients with advanced PC, if confirmed by prospective studies and larger patient numbers.

Makale detayları

Prognostic importance of Mean Platelet Volume/ Platelet Ratio Before Treatment in Patients with Metastatic Pancreatic Cancer

Yazarlar:

N.A.

Yayıncı:

Dicle University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Dicle Tıp Dergisi Vol.50 Issue 1, pp.51-59

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001285397

pISSN:

1300-2945

Metatatik pancreatic cancer

Mean platelet volume (MPV)

Progression-free survival(PFS)

Sayı

Makale detayları

Prognostic importance of Mean Platelet Volume/ Platelet Ratio Before Treatment in Patients with Metastatic Pancreatic Cancer

Yazarlar: N.A.

Yayıncı: Dicle University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Dicle Tıp Dergisi Vol.50 Issue 1, pp.51-59

Belge Tipi: Makale

Yayın Tarihi: 3/2023

Belge Dili: Türkçe

Document ID (Org No.): 2001285397

pISSN: 1300-2945

Metatatik pancreatic cancer

Mean platelet volume (MPV)

Progression-free survival(PFS)

Sayı

Yazarlar:

N.A.

Yayıncı:

Dicle University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Dicle Tıp Dergisi Vol.50 Issue 1, pp.51-59

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001285397

pISSN:

1300-2945